prenatal diagnosis of trisomy mosaic of double trisomy 11 and trisomy 12 in a single colony on amniocentesis in pregnancies with a favorable result

We attend prenatal diagnosis of trisomy mosaic of double trisomy 11 and trisomy 12 in amniocentesis with a single colony in 23 years outcome.A benefit women undergoing amniocentesis at 24 weeks of gestation because of congenital fetal bowel dilation. Amniocentesis revealed a karyotype 48, XX, + 11, + 12 [1] / 46, XX [24]. In the 25 colonies cultured amniocytes, all five cells in one colony had karyotype 48, XX, + 11, + 12, while the remaining 24 colonies had karyotype 46, XX. 

The karyotype of normal parents. Repeat amniocentesis performed at 26 weeks gestation. interphase fluorescence in situ hybridization (FISH), array comparative GENTAUR genomic hybridization (aCGH) and fluorescent quantitative polymerase chain reaction (QF-PCR) is applied to the uncultured amniocytes, and conventional cytogenetic analysis applied to cultured amniocytes. Interphase FISH analysis showed no signal of trisomy 11 and trisomy 12 was no signal in 102 uncultured amniocytes. QF-PCR analysis excluded uniparental disomy (UPD) 11 and 12. 

UPD aCGH analysis showed no genomic imbalances. The repeated amniocentesis cultured amniocytes have karyotype 46, XX in 13/13 colony. In the long run, a 3445-g healthy baby girl was delivered with no phenotypic abnormalities except imperforate anus and perianal fistula. Umbilical cord blood has the karyotype 46, XX in 40/40 lymphocytes. interphase FISH analysis postnatal buccal cells and bladder cells revealed trisomy 11 and 12 signal in 11/111 (9.9%) of the 

buccal cells compared with 3% in normal controls, and 3/103 (2.9%) compared to the bladder cell 0 , 98% in normal control.Mosaicism to double trisomy trisomy 11 and trisomy 12 in a single colony amniocentesis without UPD UPD 11 and 12 can be associated with a favorable outcome.

Use inhibitor of the renin-angiotensin-aldosterone system and risk COVID-19 requires admission to the hospital: a case study-population

Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) can influence individuals to COVID-19 severe; However, the epidemiological evidence is lacking. We report the results of a case-population studies conducted in Madrid, Spain, since the outbreak of this COVID-19.In-population case studies, we selected consecutive patients aged 18 years or older with PCR-confirmed diagnosis COVID-19 requires admission to hospital from seven hospitals in Madrid, who had been treated between March 1 and March 24th 2020. 

As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and the date admission to the hospital (month and day; the index date), from Base de datos para la Investigacion Farmacoepidemiológica en Atención Primaria (BIFAP), primary health care database of Spain, the last available year (2018). We extracted information about comorbidities and prescription until the month before the index date (ie, the current use) of electronic clinical records both cases and controls. An interesting result is the patient's admission to hospital with COVID-19. To minimize confounding by indication, the primary analysis focused on assessing the relationship between COVID-19 requires admission to the hospital and RAAS inhibitor use compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, gender, and cardiovascular comorbidities and risk factors, using conditional logistic regression. 

The study protocol has been registered in the European Union Electronic Register of Post-Authorization Studies, 

.

EUPAS34437.We collect data for 1139 cases and 11 390 population controls. Among the cases, 444 (39 · 0%) were female and the average age was 69 · 1 years (SD 15 · 4), and even if it fits on gender and age, the proportion is significantly higher than the case have a history of cardiovascular disease ( OR 1 · 98, 95% CI 1 · 62-2 · 41) and risk factors (1 · 46, 1 · 23-1 · 73) than the control. Compared with users of other antihypertensive drugs, users RAAS inhibitors have an OR for COVID-19 requires admission to hospital 0 · 94 (95% CI 0 · 77-1 · 15). No increased risk was observed with both inhibitors of angiotensin-converting enzyme (OR 0 · 80, 0 · 64-1 · 00) or angiotensin-receptor blockers (1 · 10, 0 · 88-1 · 37). Gender, age, and background cardiovascular risk does not modify the OR between the use of inhibitors of RAAS and COVID-19 requires admission to the hospital, while https://gentaur.com/categories decreasing the risk of COVID-19 requires admission to hospital was found among patients with diabetes that users RAAS inhibitors (OR 0 ·

 53, 95% CI 0 · 34-0 · 80). Adjusted OR of similar severity-19.RAAS COVID inhibitors do not increase the risk of COVID-19 requires admission to the hospital, including fatal cases, and they treated the intensive care unit, and should not be stopped to prevent severe cases of COVID- 19.Instituto de Salud Carlos III.